Amgen Inc. (AMGN)
Amgen Shrugs Off Bone Density Concerns Related to Obesity Candidate
AMGN says there was no connection between the administration of MariTide and bone mineral density changes.
Amgen Inc. (AMGN) UBS Global Healthcare Conference (Transcript)
Amgen Inc. (NASDAQ:AMGN ) UBS Global Healthcare Conference November 13, 2024 1:15 PM ET Company Participants Peter Griffith - CFO Narimon Honarpour - SVP, Global Development Justin Claeys - VP, IR Conference Call Participants Trung Huynh - UBS Trung Huynh Okay, great. I think that's quarter past.
Amgen initiated with a Neutral at Citi
Citi initiated coverage of Amgen with a Neutral rating and $335 price target. The company's growth picture hinges on MariTide clinical success and to a lesser degree, the trajectory for several newer products, the analyst tells investors in a research note. The firm says MariTide likely will need to demonstrate monthly dosing, 15%-20% minimum weight loss, and less than 10% discontinuations along with benign safety, the analyst tells investors in a research note.
Signal Says Pharma Stock Selloff Should Be Over
Shares of pharmaceutical giant Amgen (AMGN) are attempting to bounce back after suffering a steep drop of 7.1% yesterday, following reports that the company's weight-loss drug, MariTide, triggers a significant loss in bone density. Last seen holding above $300, AMGN could be due for more chart recovery if past is precedent.
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
On Tuesday, a Cantor analyst wrote that additional data from Amgen's experimental weight loss injection, MariTide, suggests a new potential safety risk tied to the drug.
Trade Tracker: Joe Terranova sells Amgen and buys XBI
Joe Terranova, senior managing director for Virtus Investment Partners, joins CNBC's 'Halftime Report' to discuss his latest portfolio moves.
What's Happening With Amgen Stock?
Amgen stock (NASDAQ: AMGN) saw a 7% fall on Tuesday, November 12, after an update on the progress with its weight-loss drug — MariTide. An early-stage trial for the drug showed loss of bone density, which could be a potential safety risk.
Amgen sees no bone safety concerns around experimental obesity drug
Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a day after data from an early-stage study dragged its stock 7% lower.
Amgen sinks as Cantor flags issues with obesity drug
Olivia Brayer, Cantor Fitzgerald, joins 'Fast Money' to discuss Amgen shares sliding on bone density data.
Amgen stock falls as analysts mull over weight loss drug's bone density data
Shares of Amgen fell as analysts chewed over bone density loss data from an early-stage trial on its experimental weight loss injection, MariTide. While some analysts called the additional data a potential safety risk, others said the share move was an overreaction and that more data on a larger group of patients is needed.
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Amgen Q3 Earnings Beat, Sales In Line, Obesity Candidate in Focus
AMGN beats third-quarter estimates for earnings and matches the same for sales. It slightly raises 2024 sales guidance but narrows the EPS range.
